Viaderma Stock Number Of Shares Shorted
| VDRM Stock | USD 0.01 0.00 0.00% |
Viaderma fundamentals help investors to digest information that contributes to Viaderma's financial success or failures. It also enables traders to predict the movement of Viaderma Pink Sheet. The fundamental analysis module provides a way to measure Viaderma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viaderma pink sheet.
Viaderma |
Viaderma Company Number Of Shares Shorted Analysis
Viaderma's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Viaderma has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Viaderma Fundamentals
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| Gross Profit | 37.63 K | |||
| EBITDA | (592.43 K) | |||
| Net Income | (1.52 M) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Current Ratio | 0.29 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Beta | -0.42 | |||
| Market Capitalization | 82.27 K | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Working Capital | (445 K) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
| Z Score | -28.3 | |||
| Net Asset | 426.56 K |
About Viaderma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viaderma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viaderma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viaderma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.